Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 10917–10922 | Cite as

Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer

  • Shuting Ding
  • Nan Liu
  • Huanyu Zhao
  • Guiyang Jiang
  • Xiupeng Zhang
  • Enhua Wang
Original Article
  • 257 Downloads

Abstract

We used immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) to evaluate anaplastic lymphoma kinase (ALK) protein expression and gene rearrangements, respectively, in 283 cases of wild-type epidermal growth factor receptor (EGFR) non-small cell lung cancer biopsy specimens. Immunohistochemistry was positive for ALK in 52 cases (18.4 %), and there was no significant difference in staining between various monoclonal antibodies (Roche ALK test kit, D5F3, p-ALK, and EML4-ALK). On RT-PCR, 36 cases (12.7 %) were positive for ALK. Immunohistochemistry and RT-PCR were both positive in 35 cases and both negative in 230 cases, and both have a high consistency (265/283, 93.6 %). Including 17 cases, immunohistochemistry was positive but RT-PCR was negative, and in one case, immunohistochemistry was negative but RT-PCR was positive. On fluorescence in situ hybridization (FISH) testing of these 18 cases, only three cases were positive (one RT-PCR was positive; two immunohistochemistry were positive). There is a high prevalence of ALK positivity in wild-type EGFR non-small cell lung cancer. Immunohistochemistry for the detection of ALK gene rearrangements was highly consistent with RT-PCR, and thus, it is a good screening tool but produces false positive results that necessitate further screening by RT-PCR or FISH.

Keywords

Immunohistochemistry Non-small cell lung cancer ALK 

Notes

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (no. 81272606 to Enhua Wang)

Compliance with ethical standard

Conflicts of interest

None.

References

  1. 1.
    Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46(10):1773–80.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chuang JC, Nezl JW, Niu XM, Wakelee HA. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: current data and future prospects. Lung Cancer. 2015;90(1):1–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, Feng Y, et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013;15(3):341–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15(4):415–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim H, Chung JH. Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. Transl Lung Cancer Res. 2015;4(2):149–55.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Enqelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004–12.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561–71.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Onco. 2011;6(3):466–72.CrossRefGoogle Scholar
  10. 10.
    Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34(8):1155–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, et al. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One. 2014;23:9(9).Google Scholar
  12. 12.
    Savic S, Diebold J, Zimmermann AK, Jochum W, Baschiera B, Grieshaber S, et al. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer. 2015;89(2):104–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Yuan L, Yunjian P, Rui W, Yihua S, Haichuan H, Shen X, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. Plos One. 2013;8(7):e69016.CrossRefGoogle Scholar
  14. 14.
    Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small lung carcinoma: IHC score algorithm for FISH. J Thorac Onocol. 2011;6(3):459–65.CrossRefGoogle Scholar
  15. 15.
    Wang R, Pan Y, Li C, Hu H, Zhang Y, Li H, et al. The use of quantitative real- time reverse transcriptase PCR for 5′ and 3′ portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012;18(17):4725–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang J, Cai Y, Dong Y, Nong J, Zhou L, Liu G, et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS One. 2014;3:9(7).Google Scholar
  17. 17.
    Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Onocol. 2014;9(5):631–8.CrossRefGoogle Scholar
  18. 18.
    Ying L, Yongwen L, Tong Y, Sen W, Jing W, Wang M, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non small cell lung cancer. Plos One. 2013;8(1):e52093.CrossRefGoogle Scholar
  19. 19.
    Kang HJ, Lim H-J, Park JS, Cho Y-J, Yoon H-I, Chung JH, et al. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med. 2014;108(2):388–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Aswin S, Socinski MA, Burns TF, University of Pittsburgh, Hillman Cancer Center Research Pavilion, Division of Hematology-Oncology, et al. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opin Pharmacother. 2014;15(18):2693–708.CrossRefGoogle Scholar
  21. 21.
    Hutarew G, Hauser-Kronberger C, Strasser F, Llenos IC, Dietze O. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology. 2014;65(3):398–407.CrossRefPubMedGoogle Scholar
  22. 22.
    Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res. 2014;3(2):70–4.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Cruz-Rico G, Avilés-Salas A, Segura-González M, Espinosa-García AM, Ramírez-Tirado LA, Morales-Oyarvide V, et al. Diagnosis of EML4-ALK translocation with FISH, immunohistochemistry, and real-time polymerase chain reaction in patients with non-small cell lung cancer. Am J Clin Oncol. 2015;11.Google Scholar
  24. 24.
    Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015;20(3):316–22.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Demidova I, Barinov A, Savelov N, Gagarin I, Grinevitch V, Stroiakovaski D, et al. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Arch Pathol Lab Med. 2014;138(6):794–802.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Shuting Ding
    • 1
  • Nan Liu
    • 1
  • Huanyu Zhao
    • 1
  • Guiyang Jiang
    • 1
  • Xiupeng Zhang
    • 1
  • Enhua Wang
    • 1
  1. 1.Department of Pathology, First Affiliated Hospital and College of Basic Medical SciencesChina Medical UniversityShenyangChina

Personalised recommendations